Biotechnology company
Appears in 1 story
Acquisition target
GSK agreed to pay $10.6 billion in cash for Nuvalent, a Cambridge, Massachusetts biotech with two lung cancer drugs awaiting U.S. approval. At $124 a share, the price is about 40% above where Nuvalent traded before the deal. It is GSK's biggest acquisition in more than a decade.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
